Home » News » CRISIL Research
Feb 20, 2013, 12.31 PM IST | Source: Moneycontrol.com

Apollo Hospitals Enterprise on a strong footing: CRISIL

CRISIL Research has come out with its report on Apollo Hospitals Enterprise. The research firm have raised their earnings estimates factoring in strong performance by the pharmacy business and higher-than-expected traction in hospitals in tier II cities. CRISIL has maintained a fundamental grade of 5/5 to the company.

CRISIL Research has come out with its report on Apollo Hospitals Enterprise . The research firm have raised their earnings estimates factoring in strong performance by the pharmacy business and higher-than-expected traction in hospitals in tier II cities. CRISIL has maintained a fundamental grade of 5/5 to the company.

Apollo Hospitals Enterprise's (Apollo's) Q3FY13 standalone results exceeded CRISIL Research's expectations. Revenues grew 20% y-o-y driven by growth in the pharmacy and healthcare services businesses. EBITDA margin was up by 55 bps y-o-y; adjusted PAT grew 25% y-o-y. Despite a seasonally weak quarter, hospitals in the Chennai and Hyderabad clusters recorded steady growth. Hospitals in tier II cities too reported healthy growth in occupancy and margins. The pharmacy business continued its momentum, registering 29% y-o-y growth. We have raised our earnings estimates factoring in strong performance by the pharmacy business and higher-than-expected traction in hospitals in tier II cities. We maintain our fundamental grade of 5/5.

Chennai, Hyderabad clusters stable; hospitals in tier II cities record robust growth
Q3 typically witnesses a decline in healthcare activity as it encompasses the festive season. Despite the seasonally weak quarter, the Chennai cluster reported revenue growth of 1.6% q-o-q and 11.6% y-o-y. The Hyderabad cluster's revenue declined 1.5% q-o-q but was up 16.4% y-o-y. Hospitals in tier II cities of Bhubaneswar, Madurai, Karaikudi and Karur posted robust revenue growth of 20%+ y-o-y with improvement in operating parameters.

Pharmacy business maintains momentum; growing share of private labels is positive
The pharmacy business recorded strong revenue growth of 29.3% y-o-y and 4.7% q-o-q to Rs 2,905 mn. Revenues per store grew 15.5% y-o-y and 1.3% q-o-q to Rs 2.01 mn. EBITDA margin improved 70 bps y-o-y (down 20 bps q-o-q) to 2.7%. Expansion in mature stores' margins and 200 bps increase in contribution from private label goods to 5% aided margin growth. Forty-six new stores were added during the quarter; Apollo has 1,445 pharmacy stores as of Q3FY13. Going forward, the management plans to add 200 stores every year.

Divestment in Apollo Health Street in sync with strategy to focus on core business
Apollo has entered into an agreement with Sutherland Global Services (Sutherland) to sell 39.4% stake in Apollo Health Street (AHS). Sutherland will acquire 100% equity of AHS for Rs 5,300 mn; this values Apollo's stake at Rs 2,100 mn (1.1x its investment). We believe this is positive for the company as it will help Apollo to focus on core healthcare services and pharmacy businesses. Investment in AHS has given negligible returns; hence, deployment of proceeds in the healthcare business, which has higher profitability, will support return ratios.

Capacity additions on track, albeit few delays; 1,000 beds to come up by FY14
Although there has been a delay of six-nine months in facilities in Mumbai, Trichy and Indore, CRISIL Research does not consider it alarming. Apollo plans to add 3,000 beds over the next three years. The total capex outlay is Rs 21.7 bn; of this, Rs 5.1 bn has been spent till Q3FY13. The balance is likely to be funded through a mix of debt, internal accruals and proceeds from the AHS deal. We expect hospitals in Ayanambakkam and Bengaluru (total 325 beds) to commence operations by FY13-end, another 1,000 beds to come up by FY14.

Earnings estimates revised upwards; fair value raised to Rs 982 per share
Factoring in strong performance, we have raised our revenue estimates by 10% and 15% and earnings estimates by 10% and 17% for FY13 and FY14, respectively. We continue to use the discounted cash flow (DCF) method to value Apollo. In line with the revision and rolling forward of projections to FY15, the fair value is raised to Rs 982 from Rs 655.

Disclaimer: This report (Report) has been commissioned by the Company/Investor/Exchange and prepared by CRISIL. The report is based on data publicly available or from sources considered reliable by CRISIL (Data). However, CRISIL does not guarantee the accuracy, adequacy or completeness of the Data / Report and is not responsible for any errors or omissions or for the results obtained from the use of Data / Report. Opinions expressed herein are CRISIL's opinions as on the date of this Report.  The Data / Report are subject to change without any prior notice. Nothing in this Report constitutes investment, legal, accounting or tax advice or any solicitation, whatsoever. The Report is not a recommendation to buy / sell or hold any securities of the Company. CRISIL especially states that it has no financial liability, whatsoever, to the subscribers / users of this Report. This Report is for the personal information of the authorized recipient only. This Report should not be reproduced or redistributed or communicated directly or indirectly in any form to any other person or published or copied in whole or in part especially outside India, for any purpose.

© CRISIL Limited . All Rights Reserved. Published under permission from CRISIL"

To read the full report click here

Set email alert for

ADS BY GOOGLE

Buy & sell politicians on Power Play
- the political stock exchange

Price Update

Arvind Kejriwal

1715.88 5.77 0.34%

35759

Bought today

13846

Sold today

0.32%

User holding

video of the day

Chandra says satisfied with TCS' FY14, FY15 to be better

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.